Nurix Therapeutics (NRIX) Current Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has reported Current Leases for 6 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Leases fell 38.47% year-over-year to $3.2 million; the TTM figure through May 2026 stood at $3.2 million (down 38.47% YoY), while the FY2025 annual figure was $2.8 million, down 64.76% from the prior year.
• Current Leases advanced to $3.2 million in Q2 2026 per NRIX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Current Leases topped out at $8.0 million in Q4 2024 and bottomed at $2.8 million in Q4 2025.
• Historically, Current Leases has averaged $5.6 million across 5 years, with a median of $5.5 million in 2022.
• Annual changes were most pronounced in 2022 — Current Leases jumped 43.75% — and 2025, when it tumbled 64.76%.
• Nurix Therapeutics' Current Leases stood at $5.5 million in 2022, then soared by 35.42% to $7.5 million in 2023, then climbed by 7.01% to $8.0 million in 2024, then sank by 64.76% to $2.8 million in 2025, then advanced by 14.06% to $3.2 million in 2026.
• Business Quant data shows NRIX's Current Leases at $3.2 million in Q2 2026, $3.2 million in Q1 2026, and $2.8 million in Q4 2025.